Cochrane Abstracts
Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tenofovir or Zidovudine in Three‐drug Combination Therapy With One Nucleoside Reverse Transcriptase Inhibitor and One Non‐nucleoside Reverse Transcriptase Inhibitor for Initial Treatment of HIV Infection in Antiretroviral‐naïve Individuals." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three‐drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non‐nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals.
Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three‐drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non‐nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals. Accessed April 21, 2026.
Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three‐drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non‐nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals
Tenofovir or Zidovudine in Three‐drug Combination Therapy With One Nucleoside Reverse Transcriptase Inhibitor and One Non‐nucleoside Reverse Transcriptase Inhibitor for Initial Treatment of HIV Infection in Antiretroviral‐naïve Individuals [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 April 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three‐drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non‐nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals
ID - 432835
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three‐drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non‐nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
